Adma Biologics reported $59.23M in EBIT for its fiscal quarter ending in March of 2026.





Ebit Change Date
Adma Biologics USD 59.23M 3.52M Mar/2026
Alnylam Pharmaceuticals USD 112.6M 24.99M Jun/2026
BioCryst Pharmaceuticals USD 98.46M 161.92M Jun/2026
Minerva Neurosciences USD -4.37M 1.71M Sep/2024
Novavax USD 20.94M 100.32M Dec/2025
Omeros USD -48.15M 7.25M Sep/2023
Takeda JPY 201.42B 215.04B Jun/2026